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Allergies are widely considered to be misdirected
type 2 immune responses, in which immunoglobulin
E (IgE) antibodies are produced against any of a
broad range of seemingly harmless antigens. How-
ever, components of insect venoms also can sensi-
tize individuals to develop severe IgE-associated
allergic reactions, including fatal anaphylaxis, upon
subsequent venom exposure. We found that mice in-
jected with amounts of honeybee venom similar to
that which could be delivered in one or two stings
developed a specific type 2 immune response that
increased their resistance to subsequent challenge
with potentially lethal amounts of the venom. Our
data indicate that IgE antibodies and the high affinity
IgE receptor, FcεRI, were essential for such acquired
resistance to honeybee venom. The evidence that
IgE-dependent immune responses against venom
can enhance survival in mice supports the hypothe-
sis that IgE, which also contributes to allergic disor-
ders, has an important function in protection of the
host against noxious substances.
INTRODUCTION
Allergies, which afflict 20%–30% of people worldwide, are detri-
mental immune responses against any of a large variety of envi-
ronmental antigens (Pawankar et al., 2012). Such antigens
(called allergens) share the ability to elicit acquired type 2
immune responses, which are orchestrated by CD4+ T helper
type 2 (Th2) cells and include the production of allergen-specific
immunoglobulin E (IgE) antibodies (Galli and Tsai, 2012; Paul and
Zhu, 2010; Pulendran and Artis, 2012). During infections with hel-
minthes and certain other parasites, IgE-associated Th2 cell-
mediated responses are thought to contribute to host defense
(Finkelman et al., 2004; Fitzsimmons and Dunne, 2009; Pulen-
dran and Artis, 2012; Stetson et al., 2004). However, when IgE-
associated immune responses are directed against other types
of allergens, such as those in foods or medicines, allergen expo-Isure of certain sensitized individuals can induce anaphylaxis, an
acute, catastrophic, and potentially fatal systemic reaction (Fin-
kelman, 2007; Portier and Richet, 1902). Becausemost allergens
do not represent a threat to the nonsensitized host, Th2 cell
responses resulting in antigen-specific IgE antibodies to such
allergens are widely considered to be misdirected and maladap-
tive immune responses (Artis et al., 2012; Holgate and Polosa,
2008).
In 1991, Margie Profet suggested that the common feature of
most allergens is their origin from sources (such as nuts,
seafood, or venoms), which either might (e.g., foods) or always
(e.g., venoms) contain toxins (Profet, 1991). Profet also pro-
posed that allergic reactions (manifested as immediately occur-
ring symptoms, such as coughing or diarrhea) evolved as a
defense mechanism that allows the sensitized host to respond
immediately to, and to neutralize and/or avoid, noxious sub-
stances that might be indicative of potentially life-threatening
situations (Profet, 1991). However, until recently (Palm et al.,
2012), Profet’s ‘‘toxin hypothesis’’ was largely ignored by the
scientific community and, to date, supporting experimental evi-
dence has been missing.
In mammals, venoms provoke an innate inflammatory
response and pathology related to the biological activities of
the toxic components (Habermann, 1972; Mukherje et al.,
2000; Risch et al., 2009). Venoms also can induce allergic sensi-
tization and development of specific IgE antibodies (Annila,
2000; Charavejasarn et al., 1975; Jarisch et al., 1979; Saelinger
and Higginbotham, 1974; Wadee and Rabson, 1987), which
bind to the high affinity IgE receptor, FcεRI, on tissue mast cells
(MCs) and blood basophils, priming them to release mediators of
allergy and anaphylaxis upon subsequent venom exposure
(Charavejasarn et al., 1975; Finkelman, 2007; Galli and Tsai,
2012; Oettgen and Geha, 1999; Saelinger and Higginbotham,
1974). MCs also can be activated directly by certain venoms,
in the absence of specific IgE, and work in mice indicates that
innate functions of MCs, including degradation of venom toxins
by MC-derived proteases, can enhance host resistance to the
venoms of certain arthropods (including the honeybee) and rep-
tiles (Akahoshi et al., 2011; Metz et al., 2006; Schneider et al.,
2007). However, it is not known whether acquired type 2 immu-
nity against venoms also can enhance host defense.
We found that a type 2 immune response and associated IgE
antibodies against honeybee venom were able to increase hostmmunity 39, 963–975, November 14, 2013 ª2013 Elsevier Inc. 963
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an effect that was mediated by FcεRI. Our data indicate that
one function of IgE, which is best known for its role in allergic
reactions, is to protect the host against noxious substances.
RESULTS
Mice Develop an Antigen-Specific Th2 Cell Response
after Immunization with Honeybee Venom
Honeybee (Apis mellifera) venom (BV) consists of a mixture of
cytolytic peptides (e.g., melittin), enzymes (e.g., phospholipase
A2 [PLA2; considered the main allergen in BV]), hyaluronidase,
neurotoxins, and bioactive amines (Habermann, 1972) and
accounts for the majority of venom allergies in humans (Bilo´
et al., 2005). To assess their susceptibility to BV, we injected
naive wild-type (WT) Th1 cell response-prone C57BL/6 mice
and Th2 cell response-prone BALB/c mice subcutaneously
(s.c.) with increasing total amounts of complete, unprocessed
BV at one to five different sites. Each injection contained 100
to 200 mg of BV, mimicking the amount of venom typically found
in individual honeybees (our immunization dosages therefore
correspond to 1 to 5–10 honeybee stings; Metz et al., 2006;
Schmidt, 1995) (Figures 1A to 1C). Acute reactions to BV were
characterized by dose-dependent reductions in both body
temperature (Figures 1D and 1F) and survival (Figures 1E and
1G). Similar results were obtained with Russell’s viper venom,
which also induced dose-dependent toxicity (see Figures S1A
to S1G available online).
Honeybee stings can induce a Th2 cell-mediated immune
response associated with BV-specific IgE antibodies, which
can prime some individuals to exhibit anaphylaxis in response
to a subsequent sting (Annila, 2000). Mice can develop Th2
cell-mediated responses to BV when they are immunized with
BV admixed with adjuvants such as Freund’s complete adjuvant
(Saelinger and Higginbotham, 1974) or aluminum hydroxide
(Charavejasarn et al., 1975). We tested whether injections of
whole BV (without added adjuvants) also could induce type 2 im-
munity in mice (Figure 2A; Figure S2A).
We assessed responses to BV of primary T cells from draining
inguinal lymph nodes (ILNs) from C57BL/6 or BALB/c mice
5 days after injection of either PBS or a sublethal dose of BV
(i.e., one not resulting in the death of significant numbers of
animals [p = 0.32 and p = 0.07 in Figures 1E and 1G, respec-
tively]). CD4+ ILN cells from PBS-injectedmice did not proliferate
upon BV stimulation, whereas stimulation with whole BV (Figures
2B and 2C; Figures S2B and S2C) or with purified phospholipase
A2 (PLA2 [data not shown]) induced substantial proliferation of
CD4+ ILN cells from BV-injected mice, as reflected by an
increased percentage of CFSElo cells. Moreover, upon BV stim-
ulation, ILN cells from BV-, versus PBS-, injected mice produced
increased amounts of the Th2 cell-associated cytokines inter-
leukin-13 (IL-13) (Figures 2B and 2C; Figures S2B and S2C),
IL-4, and IL-5, but no, or only low amounts of, the Th1 cell-asso-
ciated cytokine interferon-g (IFN-g) (Figure 2D; Figure S2D).
Two weeks after injection of sublethal amounts of BV, we
measured serum titers of BV-specific IgG1 and total IgE, the
two antibody isotypes associated with Th2 cell immune re-
sponses in mice. One, 2 or 3 s.c. injections of 200 mg BV induced
significant elevation of BV-specific IgG1 (p < 0.05, Figure 2E) and964 Immunity 39, 963–975, November 14, 2013 ª2013 Elsevier Inc.total IgE (p < 0.05, Figure 2F) antibodies in C57BL/6 mice. Mice
on the Th2 cell-prone BALB/c background also developed
marked increases in BV-specific IgG1 (but without significant
increases in total IgE) when immunized with BV (Figures S2E
and S2F). Together, our results show that mice can develop
type 2 immune responses after exposure to amounts of BV
that mimic actual bee stings.
Type 2 Immunity to Honeybee Venom Can Confer
Increased Resistance to a High Dose of Venom
Because both IgE and IgG1 antibodies can orchestrate anaphy-
laxis and other allergic reactions in mice (Finkelman, 2007; Miya-
jima et al., 1997; Oettgen and Geha, 1999; Oettgen et al., 1994),
we speculated that a BV-induced Th2 cell response might prime
mice to exhibit exacerbated reactions to subsequent BV chal-
lenge. In contrast, we found that 3 weeks after they had received
a sublethal dose of BV, such mice exhibited markedly increased
resistance to challenge with a potentially lethal dose of BV, i.e.,
43 200 mg and 53 200 mg BV for C57BL/6 and BALB/c mice,
respectively (which caused death in 90% or 70%, respectively,
of 6- to 8-week-old naive WT animals [Figures 1E and 1G]) (Fig-
ures 2G and 2H; Figures S2G and S2H). For example, C57BL/6
mice that had been immunized with as little as 13 200 mg BV
exhibited significantly less hypothermia (p < 0.001 at 1 and
6 hr, Figure 2G) and markedly enhanced survival after potentially
lethal BV challenge (Figure 2H). In BALB/c mice, even immuniza-
tion with 13 100 mg BV induced enhanced protection (Figures
S2G and S2H).
Individual sera of protected mice obtained a week after BV
challenge (Figure 2A; Figure S2A) contained BV-specific IgE
antibodies specific for BV (Figure 2I; Figure S2I) and for themajor
BV allergen PLA2 (data not shown), and such sera also markedly
increased the ability of bone-marrow-derived culturedmast cells
(BMCMCs) to degranulate in response to BV stimulation (Fig-
ure 2J; Figure S2J). Pretreatment of such pooled immune serum
(collected from immunized and challenged mice) by heating (to
ablate IgE function [Ishizaka et al., 1986; Prouvost-Danon
et al., 1977; Strait et al., 2006]) or by using an anti-mouse IgE
antibody decreased its ability to sensitize BMCMCs to degranu-
late in response to BV (i.e., 100 ng/ml and 1,000 ng/ml; Figure 2K;
Figure S2K), confirming that BV immunization induced produc-
tion of functionally active BV-specific IgE antibodies.
Both C57BL/6 and BALB/c mice injected with sublethal
amounts of BV developed a Th2 cell immune response and
exhibited increased resistance to challenge with a potentially
lethal dose of BV. This finding is especially remarkable given
that (1) BV consists of a variety of active toxins with different
mechanisms of action (Habermann, 1972; Schmidt, 1995) and
(2) type 2 immune responses against venoms (i.e., development
of anti-venom IgG1 and IgE antibodies) are classically thought to
exacerbate the outcome of subsequent venom exposure (Annila,
2000; Bilo´ et al., 2005; Charavejasarn et al., 1975; Jarisch et al.,
1979; Reimers et al., 2000; Saelinger and Higginbotham, 1974;
Wadee and Rabson, 1987).
Acquired Resistance to High-Dose Honeybee Venom
Challenge Is Dependent on Functional IgE Antibodies
Inmice, passive transfer of either antigen-specific IgE or IgG1 an-
tibodies can confer anaphylactic reactivity to naive animals
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Figure 1. Acute Systemic Responses of Naive C57BL/
6 and BALB/c Mice to Increasing Doses of BV
(A) Experimental outline.
(B and C) Schematic showing sites of s.c. injection of up to
four or five doses of BV (or PBS) in (B) C57BL/6 and (C)
BALB/c mice. Arrowheads indicate the injection sites in the
shaved area(s). Injections were carried out in alphabetical
order, depending on the number of injections. In studies of
innate responses to BV, C57BL/6 and BALB/c mice received
1–5 doses of BV or PBS (33) (see D–G below). In experiments
in which mice were challenged with high-dose BV, C57BL/6
mice always got four injections of BV (200 mg each, as shown
in B) and BALB/c mice always got five injections of BV (200 mg
each, as shown in C).
(D–G) Female (D and E) C57BL/6 and (F and G) BALB/c WT
mice were treated s.c. with the indicated doses of BV. Mock-
treated control mice received three injections of PBS. Mice
receiving 1–3 injections were treated in the back only (see B
and C, arrows a–c); mice injected four times received three
injections in the back and one in the belly (see B, arrows a–d);
mice injected five times received four injections in the back
and one in the belly (see C, arrows a–e). (D and F) Changes in
body temperature (D Temp [mean ± SEM]) and (E and G)
survival (percentage of live animals) were monitored at the
indicated times. p values are versus PBS-treated mice and
were calculated by (D and F) Student’s t test or (E and G)
Mantel-Cox test. (D–G) Data are pooled from two (for groups
receiving 43 or 53 200 mg BV) or three (all other groups) in-
dependent experiments (n = 10–19/group). *p < 0.05; **p <
0.01; ***p < 0.001 versus PBS; numbers in D, E, and G are the
p values for comparisons to PBS that were not significant (p >
0.05). See also Figure S1 for a similar set of experiments with
Russell’s viper venom.
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Figure 2. Injection of a Sublethal Dose of BV
Induces a Th2 Cell Immune Response that
Can Increase the Resistance of C57BL/6
Mice to the Hypothermia and Mortality
Caused by Subsequent Challenge with a
Potentially Lethal Dose of BV
(A) Experimental outline. For assessment of the
ILN cell response in (B)–(D), micewere injected s.c.
with 23 200 mg BV or PBS. In (E)–(J), mice were
injected with PBS, 13 100, 13 200, 23 200, or 33
200 mg BV and challenged 3 weeks later with 43
200 mg BV.
(B andC) Flow cytometry analysis of CFSE-labeled
ILN cells stimulated for 4 days with 1 mg/ml BV or
PBS. (B) Representative dot plots and (C) quanti-
fication (pooled from three independent experi-
ments) of proliferation (percentage CFSElo) and
intracellular IL-13 (percentage of IL-13+) of CD4+
ILN cells.
(D) IL-4, IL-5, IL-13, and IFN-g in supernatants of
CFSE-labeled ILN cells after 4 days of BV or PBS
stimulation in vitro.
(E) BV-specific IgG1 and (F) total IgE antibody
levels in serum obtained 2 weeks after BV immu-
nization or mock immunization with PBS.
(G) Changes in body temperature (D Temp) and (H)
survival (percentage of live animals) of mice chal-
lenged with 43 200 mg BV three weeks after BV
immunization.
(I) Titers of BV-specific IgE in sera collected 7 days
after venom challenge from all surviving mice
shown in (H).
(J) C57BL/6 BMCMCs were sensitized with sera of
individual mice, stimulated with 1 mg/ml BV, and
the amount of b-hexosaminidase (b-hex) in the cell
supernatant was measured to assess BMCMC
degranulation.
(K) Pooled serum of BV-immunized and
challenged C57BL/6 mice (BV serum, which
was either heated to eliminate the ability of IgE
to bind to FcεRI [heated], treated with rat anti-
mouse IgE [anti-IgE], or mock-treated with
PBS [untreated]) was used to sensitize C57BL/6
BMCMCs, which were then stimulated with
different concentrations of BV (100–10,000 ng/ml)
or an equivalent volume of PBS (unstimulated).
(C–F) Data are pooled from three independent
experiments (n = 13–15/group). (C to G, I and J)
Values are mean ± or + SEM (E, F, I, and J
also show values for individual mice). (K)
Values shown are mean + SD from one repre-
sentative of three independent experiments, p
values are versus (C and D) in vitro PBS-treated
cells or (E)–(H) PBS-injected mice or (K)
cells sensitized with untreated BV serum, by
(C–G, K) Student’s t test or (H) Mantel-Cox
test. *p < 0.05; **p < 0.01; ***p < 0.001 (C, D, and K)
for the indicated comparisons or (E)–(H) versus PBS; the number in (C)–(G) are the p values for the comparisons that were not significant (p > 0.05). n.d., not
detectable; ns, not significant. See also Figure S2 for data from a similar set of experiments performed in BALB/c mice.
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IgE Can Contribute to Defense against Venom(Ando et al., 1993; Finkelman, 2007; Miyajima et al., 1997). We
used passive immunization to evaluate whether the protective
effect of BV immunization might be antibody mediated (Fig-
ure S3A). Briefly, we immunized C57BL/6 mice with 23 200 mg
BV (a sublethal dose [Figure 1E] that enhanced resistance of
C57BL/6 mice to challenge with a high dose of BV [Figures 2G
and 2H]) or injected them with PBS. Three weeks later, we966 Immunity 39, 963–975, November 14, 2013 ª2013 Elsevier Inc.confirmed the presence of increased serum titers of BV-specific
IgG1 and total IgE antibodies in BV-immunized mice (Figures
S3B and S3C). We also confirmed that serum of BV-immunized
mice contained IgE antibodies that promoted BV binding to
BMCMCs via FcεRIa, the IgE-binding component of the receptor
(Figures S3D to S3F). In parallel, some of the actively immunized
mice were challenged with a high dose of BV (43 200 mg) to
AB C
Figure 3. The IncreasedResistance of Passively ImmunizedC57BL/6WTMice toChallengewith a Potentially Lethal Dose of BV IsDependent
on Functional Serum IgE
(A) Experimental outline. Donor mice were injected with 23 200 mg BV or PBS. Three weeks later, sera from PBS- or BV-injected mice (PBS serum or BV serum,
respectively) were collected (see also Figure S2), and pooled BV serum was processed in vitro to neutralize IgE function, either by heating or anti-mouse IgE
treatment (heated BV serum or anti-IgE BV serum, respectively). Age-matched recipient mice were anesthetized and transfused i.v. with serum 22 hr before
challenge with 43 200 mg BV.
(B) Changes in body temperature after challenge (D Temp [mean ± SEM]) and (C) survival (percentage of live animals) were monitored at indicated time points.
Data are pooled from experiments obtained with two different pools of serum and a total of four independent experiments (n = 14–20/group). p values are
calculated by (B) Student’s t test and (C) Mantel-Cox test. *p < 0.05; **p < 0.01; ***p < 0.001 for the indicated comparisons. See also Figure S3.
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IgE Can Contribute to Defense against Venomconfirm successful immunization (Figures S3G and S3H, dashed
lines).We then transferred pooled sera (derived frommicemock-
immunized with PBS [‘‘PBS serum’’] or immunized with BV [‘‘BV
serum’’]) intravenously (i.v.) into age-matched naive WT mice
and challenged them 22 hr later with 43 200 mg BV.
Transfer of BV serum (compared to transfer of PBS serum)
conferred significantly increased resistance to high dose BV
challenge, as assessed by body temperature (p < 0.01, Fig-
ure S3G) or survival (p < 0.001, Figure S3H). Remarkably, passive
immunization was as effective as active immunization (Figures
S3G and S3H). We concluded that soluble factors in the serum
of BV-immunized mice are sufficient to increase host resistance
to a potentially lethal dose of BV.
We next used two approaches in WT mice to assess the
contribution of IgE antibodies to the protection conferred by
immune serum (Figure 3A). First, we treated the BV serum with
an anti-IgE antibody (i.e., ‘‘anti-IgE BV serum’’) before passive
immunization. This approach is straightforward but risks
inducing anaphylaxis due to formation of antibody immune-com-
plexes that in turn activate effector cells. Indeed, 5 of the 20miceIthat received anti-IgE BV serum developed severe hypothermia
and died soon after the transfusion; the other 15 mice appeared
normal and were used for the experiments shown in Figure 3. We
alsopassively immunizedmicewith heatedBVserum (Figure 3A).
Heating results in a loss of the ability of IgE to induce passive
cutaneous anaphylaxis (Prouvost-Danon et al., 1977), whereas
the function of other antibody classes, including IgG1, is not
affected (Strait et al., 2006).
Notably, either heating (Figures 3B and 3C; orange triangles)
or anti-IgE antibody treatment (Figures 3B and 3C; inverted
yellow triangles) essentially abolished the protective potential
of BV serum (Figures 3B and 3C; red diamonds) in mice chal-
lenged with 43 200 mg BV. These results support the conclusion
that IgE antibodies substantially contribute to, or may fully
account for, the immune serum’s protective effect.
Honeybee-Venom-Immunized IgE-deficient Mice Do Not
Develop Enhanced Resistance to the Venom
In order to confirm the role of IgE antibodies in acquired
host resistance against BV by using a genetic approach, wemmunity 39, 963–975, November 14, 2013 ª2013 Elsevier Inc. 967
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Figure 4. IgE, but Not IgG Antibodies, Are
Necessary for the Protective Effect of the
Adaptive Response to BV
(A) Experimental outline for (B) and (C).
(B and C) IgE-deficient (Igh-7/) or IgE-sufficient
(Igh-7+/+) BALB/c mice mice were injected with 13
100 mg BV or PBS. Three weeks later, mice were
challenged with 53 200 mg BV. (B) Changes in
body temperature (D Temp) and (C) survival (per-
centage of live animals) were monitored at the
indicated times.
(D) Experimental outline for (E) and (F). WT BALB/c
donor mice were injected with 13 100 mg BV
or PBS. Three weeks later, sera from PBS- or
BV-injected mice (PBS serum or BV serum,
respectively) were collected, and pooled BV
serum was processed in vitro to neutralize IgE
function by heating (heated BV serum). Age-
matched IgE-deficient recipient mice were
anesthetized and transfused i.v. with serum or
PBS containing monoclonal anti-DNP-IgE (an
amount equivalent to the total IgE content of
transferred BV serum) 22 hr before challenge with
53 200 mg BV.
(E) Changes in body temperature after challenge
(D Temp) and (F) survival (percentage of live ani-
mals) were monitored at the indicated times. Data
are pooled from (B and C) four independent ex-
periments (n = 17–19/group) or (E and F) from
experiments obtained with two different pools of
serum and a total of three independent experi-
ments (n = 8–14/group). (B and E) Values are
mean ± SEM; p values are calculated by (B and E)
Student’s t test or (C and F) Mantel-Cox test. *p <
0.05; **p < 0.01; ***p < 0.001 for the indicated
comparisons; the numbers in (B), (C), (E), and (F)
are the p values for indicated comparisons that
were not significant (p > 0.05). See also Figure S4.
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IgE Can Contribute to Defense against Venomattempted active immunization of mice genetically lacking
IgE (BALB/c-Igh-7/) (Figures S4A to S4C; Figure 4A). Fourteen
days after immunization with 13 100 mg BV, the serum of
IgE-deficient animals contained specific IgG1 antibodies at titers
comparable to WT controls and, as expected, no detectable
IgE (Figures S4D and S4E). As observed in prior experiments
(Figures S2G and S2H), BV-immunized WT mice were sig-
nificantly more resistant to challenge with 53 200 mg BV than
were PBS mock-immunized mice (p < 0.01, Figures 4B and
4C). In contrast, BV-immunized IgE-deficient mice were less968 Immunity 39, 963–975, November 14, 2013 ª2013 Elsevier Inc.resistant to high-dose BV challenge
than were PBS mock-immunized IgE-
deficient mice (Figures 4B and 4C).
Notably, IgE-deficient mice that were
passively immunized with untreated
BALB/c BV serum (that had been
confirmed to confer protection in BALB/c
WT mice challenged with 53 200 mg BV
[data not shown]) developed less
hypothermia and exhibited lower mortal-
ity than mice that had received heated
BV serum or PBS serum (Figures 4D–
4F). By contrast, transfer of dinitrophenyl(DNP)-specific monoclonal IgE antibody (that was functionally
active in both IgE-deficient and WT mice [Figures S4F to S4H]),
in amounts equivalent to the amounts of IgE transferred in
BV serum, did not influence the resistance of recipient IgE-defi-
cient mice to BV challenge (Figures 4D–4F).
Together with the results of our serum transfer experiments
in WT C57BL/6 mice (Figure 3) these findings support
the conclusion that type 2 immune responses can enhance
host resistance to honeybee venom by IgE-dependent
mechanisms.
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Figure 5. FcεRIa IgE Binding and FcεRIg
Signaling Are Required for BV-Immunized
Mice to Exhibit Increased Resistance
against a Potentially Lethal Dose of BV
(A) Experimental outline for (B)–(E).
(B and C) C57BL/6 Fcer1g/ and WT mice and (D
and E) BALB/c Fcer1a/ and WT mice were
injected with 23 200 mg BV or PBS (23), or 13
100 mg BV or PBS (13), respectively. Three weeks
later, (B and C) mice of C57BL/6 background were
challenged with 43 200 mg BV and (D and E) mice
of BALB/c background were challenged with 53
200 mgBV. (B and D) Changes in body temperature
(D Temp) and (C and E) survival (percentage of live
animals) were monitored at indicated time points.
(F) Experimental outline for (G) and (H). PBS serum
or BV serum from WT C57BL/6 ‘‘donor’’ mice (see
Figure S2A) were transferred i.v. into recipient
C57BL/6 WT, Fcer1g/, or Fcer1a/ mice 22 hr
before challenge with 43 200 mg BV.
(G) Changes in body temperature (D Temp) and (H)
survival (percentage of live animals) were moni-
tored at the indicated times. Data are pooled (B–E)
from three independent experiments (n = 11–15/
group) or (G and H) from experiments obtained
with two different pools of serum and a total of
three to four independent experiments (n = 8–17/
group). (B–D, G) Values are mean ± SEM; p values
are calculated by (B, D, and G) Student’s t test and
(C, E, and H) Mantel-Cox test. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001 for the indicated
comparisons; the numbers in (B), (D), and (G) are
the p values for the indicated comparisons that
were not significant (p > 0.05); ns, not significant.
See also Figure S5.
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IgE Can Contribute to Defense against VenomFcεRIg and FcεRIa Are Required for IgE-Mediated
Resistance to High-Dose Honeybee Venom Challenge
Antigen- and IgE-dependent activation of MCs and basophils by
FcεRI is considered the keymechanism underlying acute allergicImmunity 39, 963–975, Nreactions (Kawakami and Kitaura, 2005;
Kinet, 1999; Rivera et al., 2008). FcεRI
contains one IgE-binding a chain, one b
chain (that can function as a signal ampli-
fier), and two signal-transducing g-chains
(referred to as FcεRIa, FcεRIb, and
FcεRIg, respectively) (Kinet, 1999; Rivera
et al., 2008); FcεRIg also participates in
the signaling of the IgG receptors FcgRI,
FcgRIII, and FcgRIV (Bruhns, 2012; Kinet,
1999). To elucidate the function of anti-
bodies in host defense against BV, we
used a genetic approach targeting cell-
mediated effects of IgG and IgE.
First, we actively immunized mice
lacking FcεRIg (C57BL/6-Fcer1g/) and
C57BL/6 WT controls with 23 200 mg
BV (a sublethal dose [Figure 1E] that
enhanced resistance of C57BL/6 mice
to challenge with a high dose of BV [Fig-
ures 2G and 2H]) or injected them withPBS (Figure S5A; Figure 5A). Naive Fcer1g/ and WT animals
exhibited similar acute systemic innate responses to initial BV in-
jection (Figures S5B and S5C) and elevated serum levels of BV-
specific IgG1 and total IgE 2 weeks later (Figures S5D and S5E).ovember 14, 2013 ª2013 Elsevier Inc. 969
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IgE Can Contribute to Defense against VenomHowever, in contrast to WT mice, BV immunization did not
protect Fcer1g/mice against challengewith a potentially lethal
dose of BV (Figures 5B and 5C). These results demonstrate the
importance of IgE and/or IgG-Fc-receptor signaling via the FcεRI
g-chain for the protective effect of this venom-specific type 2 im-
mune response.
We then assessed whether BV immunization could enhance
resistance to high dose BV challenge in BALB/c mice lacking
only the IgE-binding FcεRIa chain (BALB/c-Fcer1a/; Fig-
ure S5A; Figure 5A). Fcer1a/ andWTmice responded similarly
to 13 100 mg BV immunization (a low dose that conferred
enhanced protection to BALB/c mice upon challenge with a
high dose of BV [Figures S2G and S2H]) (Figures S5F and S5G)
and developed a BV-specific type 2 antibody response (Figures
S5H and S5I). However, in comparison to WT counterparts (Fig-
ures 5D and 5E), BV-immunized Fcer1a/ mice developed
increased hypothermia and much higher mortality upon chal-
lenge with a potentially lethal dose (53 200 mg) of BV 3 weeks
after immunization (Figures 5D and 5E). Notably, two of the three
BV-immunized WT mice that did not have detectable serum IgE
(but did develop increased BV-specific IgG1, Figure S5I) were
not protected and died within 24 hr. The importance of FcεRIa-
and FcεRIg-related signaling in the acquired resistance to BV
was supported further by passive immunization experiments in
which BV serum derived from C57BL/6 WT mice, as compared
to PBS serum, improved neither hypothermia nor survival when
transferred into C57BL/6-Fcer1g/ or C57BL/6-Fcer1a/
mice (Figures 5F–5H).
Together, our results highlight the importance of IgE binding
to FcεRIa and signaling via FcεRIg in the type 2 response-medi-
ated host resistance against BV.
Evidence for a Role for Mast Cells in IgE-Mediated
Resistance to High Dose Honeybee Venom Challenge
Our experiments indicate that IgE and signaling via FcεRI are
critical components of type 2 immune responses that increase
resistance to potentially lethal BV doses. MCs are major FcεRI-
expressing IgE effector cells (Galli and Tsai, 2012; Kinet, 1999;
Oettgen and Geha, 1999; Rivera et al., 2008), and previous
reports by our lab (Akahoshi et al., 2011; Metz et al., 2006) and
others (Schneider et al., 2007) indicate that MCs importantly
contribute to the innate resistance to certain venoms (including
BV [(Metz et al., 2006)]) and venom components (Akahoshi
et al., 2011; Metz et al., 2006; Schneider et al., 2007). We there-
fore speculated that MCs may also play an important role in
acquired resistance to BV. Consistent with a previous report
(Higginbotham and Karnella, 1971) and our in vitro experiments
(Figure 2K; Figure S2K), BV injection induced extensive MC
degranulation at injection sites in both naive mice (Figure 6A)
and mice injected 3 weeks earlier either with PBS or BV (Fig-
ure 6B). Consistent with our previous findings (Metz et al.,
2006), MC-deficient C57BL/6-KitW-sh/W-sh mice (whose MC defi-
ciency is caused by a mutation affecting expression of Kit, the
receptor for the MC survival and maturation factor stem cell
factor) and C57BL/6-Cpa3-Cre+;Mcl-1fl/fl mice (whose marked
MC deficiency and decreased numbers of basophils are not
due to c-kit mutations [Lilla et al., 2011]) were more susceptible
to challenge with 43 200 mg BV than their respective controls
(i.e., Kit+/+ and Cpa3-Cre+;Mcl-1+/+ mice) (Figures 6C to 6E).970 Immunity 39, 963–975, November 14, 2013 ª2013 Elsevier Inc.The important role of MCs in innate resistance to BV compli-
cates assessment of the contribution of MCs as potential IgE
effector cells in acquired increased resistance to BV. To deal
with this issue, we decreased the challenge dose for MC-defi-
cient mice to 33 200 mg BV (this dose caused death in 60%–
90% of naive MC-deficient mice [data not shown]) and
performed serum transfer experiments. We found that naive
MC-deficient mice that received C57BL/6 BV serum (from the
same pools of BV serum that conferred protection in C57BL/6
WT mice challenged with 43 200 mg BV [Figures S3G and
S3H, 5G and 5H]) exhibited worse survival upon BV challenge
than those passively immunized with PBS serum (Figures 6F to
6H), suggesting that MCs can contribute to IgE-mediated resis-
tance against BV.
Russell’s Viper Venom Can Induce a Protective Type 2
Immune Response Against a High Venom Dose
Finally, we were curious whether protective type 2 immunity
could be induced by another type of venom. Venomous reptiles
account for considerable morbidity and mortality in people (The-
akston et al., 2003). Together with the Indian cobra (Naja naja),
the krait (Bungarus caerulaeus), and the saw scaled viper (Echis
carinatus), the Russell’s viper (Daboia russelii) composes the
group of snakes referred to as the ‘‘Big Four,’’ which accounts
for the majority of snake-bite-related deaths in India (Simpson
and Norris, 2007). Russell’s viper venom (RVV) is a complex
mixture of growth factors and enzymes with procoagulant and
neurotoxic activities (Risch et al., 2009).
We defined sublethal and potentially lethal doses of RVV in
C57BL/6 and BALB/c mice by using 2 s.c. injections in the
back (mimicking a snake bite) containing 5–50 mg of RVV per
each 50 ml injection (Figures S1A to S1C). Five and 12.5 mg of
RVV per injection (i.e., 10 mg and 25 mg of total RVV, respectively),
which did not cause death in a substantial number of C57BL/6
animals, were chosen as the immunizing doses (Figures S1D
to S1G). Like with BV, immunization with RVV induced a type
2 immune response characterized by the development of
RVV-specific T cells with a Th2 cell profile (Figures 7A–7C; Fig-
ures S6A to S6C), as well as increased serum levels of RVV-
specific IgG1 (Figure 7D; Figure S6D) and total IgE (Figure 7E;
Figure S6E). Three weeks after immunization, the mice were
challenged with a potentially lethal dose of RVV (i.e., 23
37.5 mg RVV, which caused death in 100% of 6- to 8-week-old
naive WT animals [Figures S1E and S1G]). Compared to PBS-in-
jected mice, C57BL/6 and BALB/c mice that were immunized
with 23 12.5 mg RVV exhibited less hypothermia (Figure 7F; Fig-
ureS6F) andmarkedly improved survival (Figure 7G; FigureS6G).
When we tested mice a week after RVV challenge, we detected
functionally active RVV-specific IgE antibodies in the serum of
the protected mice (Figures 7H–7J; Figures S6H–S6J). These
results show that IgE-associated type 2 immune responses
induced by a reptile venom, i.e., Russell’s viper venom, also
can enhance resistance of the host to challenge with a high
dose of venom.
DISCUSSION
We found that injecting mice with whole honeybee venom or
Russell’s viper venom can induce the differentiation of BV- or
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Figure 6. Passive Immunization with Serum
of BV-Immunized WT Mice Fails to Increase
the Resistance against Challenge with a
Potentially Lethal Dose of BV in MC-Defi-
cient Mice
(A and B) Extent of MC degranulation (quantified
as percentage of none, moderate, and extensive
degranulated MCs) at the site of injection (back
skin) following (A) injection of PBS (13) or BV (13
200 mg) in naive mice or (B) challenge of BV (43
200 mg) in mice previously immunized with PBS or
BV, and representative Toluidine Blue-stained
back skin sections from the 30 min time point;
arrowheads indicate some nondegranulated MCs
and arrows indicate some of the extensively
degranulated MCs. In (A), PBS injection did not
cause significant MC degranulation compared to
naive animals. In (B), ‘‘0minutes’’ refers to baseline
values in back skin of mice in the two groups
obtained prior to injections of BV; BV injection
caused significant MC degranulation after 30, 180,
or 360 min in PBS or BV groups compared to the
corresponding ‘‘0’’ values.
(C) Experimental outline for (D) and (E). KitW-sh/W-sh
and Kit+/+ controls, Cpa3-Cre+-Mcl-1fl/fl, and
Cpa3-Cre+-Mcl-1+/+ controls were injected with
43 200 mg BV.
(D) Changes in body temperature (D Temp) and (E)
survival (percentage of live animals) were moni-
tored at the indicated times.
(F) Experimental outline for (G) and (H). PBS serum
or BV serum from WT C57BL/6 ‘‘donor’’ mice (see
Figure S2A) were transferred i.v. into MC-deficient
recipient KitW-sh/W-sh and Cpa3-Cre+-Mcl-1fl/fl
mice 22 hr before challenge with 33 200 mg BV.
(G) Changes in body temperature after challenge
(D Temp) and (H) survival (percentage of live
animals) were monitored at the indicated times.
Data are pooled from (C–E) two independent
experiments (n = 7–10/group) and (F–H) 2–3 in-
dependent experiments obtained with three
different pools of serum (n = 9–13/group). (A and B)
Values are mean ± SD; (D and G) values are
mean ± SEM; p values are calculated by (A and B)
chi-square, (D and G) Student’s t-test, or (E and H)
Mantel-Cox tests. *p < 0.05; **p < 0.01; ***p <
0.001 for the indicated comparisons; ns, not sig-
nificant (p > 0.05).
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IgE Can Contribute to Defense against VenomRVV-specific Th2 cells and the production of venom-specific
IgG1 and IgE antibodies. This was true in mice with genetic
biases to develop either type 1 (C57BL/6) or type 2 (BALB/c)
immune responses, suggesting that BV and RVV have strong
intrinsic abilities to induce a Th2 cell-mediated immune response
in mice. Notably, these BV- or RVV-induced IgE-associated typeImmunity 39, 963–975, N2 immune responses enhanced host
resistance to the toxicity of that venom.
To our knowledge, our findings represent
the first experimental evidence in support
of Profet’s ‘‘toxin hypothesis.’’ Profet
hypothesized that one key beneficial
function of acquired immunological re-
sponses known as ‘‘allergic responses,’’which in some clinical settings contribute to disease, is to protect
the host against venoms and other environmental toxins (Palm
et al., 2012; Profet, 1991).
We previously reported that MCs can reduce the toxicity
of certain arthropod (including BV) and reptile venoms in
mice (Akahoshi et al., 2011; Metz et al., 2006). This MC-relatedovember 14, 2013 ª2013 Elsevier Inc. 971
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Figure 7. Injection of a Sublethal Dose of
RVV induces a Type 2 Immune Response
that Can Increase the Resistance of
C57BL/6 Mice to the Hypothermia and Mor-
tality Caused by Subsequent Challenge with
a Potentially Lethal Dose of RVV
(A) Experimental outline. For assessment of the
ILN cell response in (B) and (C), mice were injected
s.c. with 23 12.5 mg RVV or PBS. In (D)–(I), mice
were injected with PBS, 23 5 mg RVV, or 23
12.5 mg RVV and challenged three weeks later with
23 37.5 mg RVV.
(B andC) Flow cytometry analysis of CFSE-labeled
ILN cells stimulated for 4 days with 1 mg/ml RVV
or PBS. (B) Representative dot plots and (C)
quantification (pooled from two independent
experiments) of proliferation (percentage CFSElo)
and intracellular IL-13 (percentage of IL-13+) of
CD4+ ILN cells.
(D) RVV-specific IgG1 and (E) total IgE antibody
levels in serum obtained 2 weeks after RVV im-
munization or mock immunization with PBS.
(F) Changes in body temperature (D Temp) and (G)
survival (percentage of live animals) of mice chal-
lenged with 23 37.5 mg RVV 3 weeks after immu-
nization with RVV or mock immunization with PBS.
(H) Titers of RVV-specific IgE in sera collected
7 days after the challenge from all surviving mice
whose data are reported in (G).
(I) C57BL/6 BMCMCs were sensitized with sera of
individual mice, stimulated with 1 mg/ml RVV, and
the amount of b-hexosaminidase (b-hex) in the cell
supernatant was measured to assess BMCMC
degranulation.
(J) Pooled serum of RVV-immunized and chal-
lenged C57BL/6 mice (RVV serum, which was
either heated to eliminate the ability of IgE to bind
to FcεRI [heated], treated with rat anti-mouse IgE
[anti-IgE], or mock-treated with PBS [untreated])
was used to sensitize C57BL/6 BMCMCs, which
were then stimulated with different concentrations
of RVV (1–100 ng/ml) or an equivalent volume of
PBS (unstimulated). (C–I) Data are pooled from
three independent experiments (C–G, n = 12–15/
group; H and I, n = 5–10/group). (C–F, H, and I)
Values are mean ± or +SEM (D, E, H, and I also
show values for individual mice). (J) Values shown
are mean + SD of triplicate values from one
representative of three independent experiments.
p values are versus (C) in vitro PBS-treated cells
and (D–F, H, I) PBS-injected mice or (J) cells
sensitized with untreated RVV serum. (C–F and
H–J) Student’s t-test or (G) Mantel-Cox test. *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 for the
indicated comparisons (C–E and J) or versus PBS
(E–J); the numbers in (C)–(E), (H), and (I), and (J) are
the p values for comparisons that were not sig-
nificant (p > 0.05). ns, not significant. See also
Figure S6 for data from a similar set of experiments
performed in BALB/c mice.
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IgE Can Contribute to Defense against Venomenhanced innate resistance to venom toxicity depends at
least in part on compounds released by activated MCs, such
as proteases (including carboxypeptidase A3 and the chymase
mMCP-4), which can degrade and neutralize certain venom
components (Akahoshi et al., 2011; Metz et al., 2006; Schneider
et al., 2007). It is tempting to speculate that the occurrence972 Immunity 39, 963–975, November 14, 2013 ª2013 Elsevier Inc.of large numbers of MCs in the skin (a frequent site of enven-
omation) and around blood vessels (representing key
‘‘access points’’ that can facilitate the systemic distribution
of venom components initially deposited locally at the site
of stings or bites, thereby increasing their systemic toxicity)
in part reflects evolutionary pressure to position MCs at
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IgE Can Contribute to Defense against Venomsites where they can rapidly respond to venoms and thereby help
to limit venom-induced pathology.
Our data, which need extension by future studies, suggest that
MCs can contribute not only to innate resistance but also to IgE-
related acquired resistance to BV. Moreover, we showed that
venom-specific IgE antibodies permitted MCs to be activated
by lower amounts of venom than are required to activate MCs
via antibody-independent innate mechanisms. It therefore
seems reasonable to propose that the release of proteases
that can degrade venom components (Akahoshi et al., 2011;
Schneider et al., 2007), and perhaps the secretion of other MC
mediators such as heparin (Higginbotham and Karnella, 1971),
by MCs activated via venom-specific IgE can contribute to the
acquired, IgE-associated enhanced resistance to bee venom.
It will be interesting to see how many additional examples of
‘‘protective Th2 cell responses’’ to toxins or other noxious
substances will be identified. It also will be important to try to
understand why some conditions of venom immunization and
challenge result in venom-directed, IgE-associated Th2 cell
responses that enhance host resistance to that venom, whereas
others prime certain unfortunate individuals to exhibit serious
and potentially fatal allergic responses, i.e., anaphylaxis, upon
subsequent venom exposure (Annila, 2000; Bilo´ et al., 2005; Re-
imers et al., 2000; Wadee and Rabson, 1987). In considering this
question, it should be noted that some people who develop Th2
cell responses to BV do not exhibit anaphylactic reactivity
despite having venom-specific IgE antibodies (Antonicelli et al.,
2002). Also, there is abundant evidence that Th2 cell-mediated
responses are subject to immune regulation, which can diminish
pathology related to IgE-dependent reactivity to the inducing
antigen, including BV (Meiler et al., 2008; Mu¨ller, 2005; Ozdemir
et al., 2011). These findings, taken together with those reported
herein, raise the possibility that anaphylaxis represents only the
most extreme and maladaptive end of a spectrum of acquired
Th2 cell-mediated immunity to venom and that includes, at the
other end of the spectrum, appropriately regulated Th2 cell
immune responses that can enhance resistance to such
venoms. It therefore will be of interest to assess the extent that
genetic and environmental factors, as well as differences in the
conditions, timing, and type of exposure to venoms or other
potentially toxic antigens, can determine whether the Th2 cell-
mediated responses induced by such antigens confer net benefit
or harm.
Although these and other questions raised by our findings
remain to be answered, our experiments demonstrate that Th2
cell-mediated immune responses and the production of IgE
antibodies, in addition to contributing to host defense against
certain parasites, can confer a survival advantage in animals
exposed to venoms.EXPERIMENTAL PROCEDURES
Mice
All animal care and experiments were carried out in accord with current
National Institutes of Health guidelines and the approval of the Stanford Uni-
versity Institutional Animal Care and Use Committee. Six to 8-week-old female
C57BL/6J or BALB/cJ mice were used in experiments involving solely WT
mice. Transgenic mouse strains were bred and housed with the respective
control mice in the local animal facilities. Transgenic C57BL/6-Fcer1g/
mice were purchased from Taconic. BALB/c-Fcer1a/ mice were originallyIobtained from Jean-Pierre Kinet (Harvard Medical School). C57BL/6-
Fcer1a/ mice were purchased from Jackson Laboratories. IgE-deficient
BALB/c (Igh-7/) mice were generated as described (Oettgen et al., 1994).
Mast-cell deficient C57BL/6-KitW-sh/W-sh mice were extensively backcrossed
onto the C57BL/6J background (Piliponsky et al., 2010) and MC- and baso-
phil-deficient C57BL/6-Cpa3-Cre; Mcl-1fl/fl mice (Lilla et al., 2011) were gener-
ated as described. Age-matched male and female transgenic mice were
used for experiments (with comparable gender distribution within the groups).
See Supplemental Experimental Procedures for additional information.
Reagents
Honeybee venom was from ALK Abello Source Materials; Russell’s viper
venom was from Sigma. Additional information on venoms and other reagents
are in the Supplemental Experimental Procedures.
Venom Injections and Active Immunization
Figure 2A outlines the active immunization protocol (see Supplemental Exper-
imental Procedures for details). Briefly, 6- to 8-week-old WT or transgenic
mice were shaved at injection sites 24 hr before injections and always
received, in the morning, one or several s.c. injections of PBS alone or contain-
ing 100 mg or 200 mg BV. For experiments with RVV, mice were immunized by
two s.c. injections of PBS alone or PBS containing 5–50 mg of RVV per injec-
tion. On day 21, mice on the C57BL/6 or BALB/c background were challenged
s.c. (without anesthesia) by four or five injections of 200 mg BV or with 2 s.c.
injections of 37.5 mg RVV (in back skin). Body temperature was measured
with a rectal thermometer immediately before and at various times after
challenge.
Measurement of Serum Antibodies
Serum antibody levels were measured with ELISA (see Supplemental Experi-
mental Procedures for details).
BMCMC Generation and Analysis of Serum for Functional IgE
See Supplemental Experimental Procedures.
Passive Immunization – Serum Preparation and Transfer
Figure S2A outlines the passive immunization protocol (see Supplemental
Experimental Procedures for details). Briefly, for experiments in Figure 3, 6-
to 8-week-old female C57BL/6J ‘‘donor’’ mice were immunized by 2 s.c. injec-
tions of 200 mg BV or with PBS alone; 3 weeks later, serum antibody levels
were measured. Aliquots of pooled serum derived from ‘‘donor’’ mice, which
had been injected with either PBS or BV are referred to as PBS serum or BV
serum, respectively. BV serum was either supplemented with a rat anti-mouse
IgE antibody (Amiri et al., 1994; Haak-Frendscho et al., 1998) for at least 30min
at room temperature (anti-IgE BV serum) or was supplemented with a rat iso-
type control antibody and left untreated (untreated BV serum) or was heated
60 min at 56C (heated BV serum). PBS serum also was supplemented with
the rat isotype control antibody at the time of the transfer. Aliquots of these
modified sera were transfused i.v. into 10- to 11-week-old female C57BL/6
‘‘recipient’’ mice. The next day, ‘‘recipient’’ mice were challenged with 4 s.c.
injections (33 back, 13 belly) of 200 mg BV. We measured body temperature
at indicated times and assessed survival over 1 week.
Flow Cytometry
See Supplemental Experimental Procedures.
Statistical Analysis
Statistical tests were performed with the software GraphPad PRISM 6. Two-
tailed Student’s t test (unpaired), two-way ANOVA, chi-square, or Mantel-
Cox tests were performed as noted in the respective figure legends. *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. = not significant (p > 0.05).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.immuni.2013.10.005.mmunity 39, 963–975, November 14, 2013 ª2013 Elsevier Inc. 973
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